Review of Second-Half Performance and Concrete On-Site Action Strategies

SK Biopharmaceuticals' U.S. subsidiary, SK Life Science, announced on October 2 that it held its "2026 Plan of Action (POA)" meeting in Chicago, Illinois, from September 29 to October 1 (local time). The company aimed to strengthen on-site execution and commercial capabilities for continued growth of its U.S. business.


The POA meeting is an event where sales personnel from U.S. pharmaceutical and biotech companies gather to review business performance, evaluate market conditions, and share future action strategies.


Donghoon Lee, CEO of SK Biopharm, is giving a presentation at the '2026 Plan of Action' meeting. SK Biopharm

Donghoon Lee, CEO of SK Biopharm, is giving a presentation at the '2026 Plan of Action' meeting. SK Biopharm

View original image

Approximately 160 participants, mainly from the U.S. sales team, attended the event to review first-half results and shifts in the market, and to discuss action strategies for continuing the growth momentum of cenobamate in the second half. They also exchanged ideas on ways to expand and leverage the commercial capabilities established in the U.S. to prepare for new product launches and portfolio expansion in the future.


SK Biopharmaceuticals' strategy is to build a global epilepsy franchise by acquiring new products and maximizing utilization of its current sales organization, based on the local commercial capabilities accumulated through cenobamate in areas such as sales, marketing, and market access. The company also plans to expand cenobamate's formulations—including oral suspension—and to broaden its indications and prescriptions to include pediatric and adolescent patients as well as primary generalized tonic-clonic (PGTC) seizures.



Donghoon Lee, CEO of SK Biopharmaceuticals, said, "Headquarters and our U.S. operations will move even faster and execute more fiercely as ‘One Team,’ continuing the growth of cenobamate, while also turning the era of multiple products into real achievements."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing